2486-71-7

Basic information

• Product Name: 4-Amino-3-chlorobenzoic acid
• Synonyms: RARECHEM AL BO 0579;BUTTPARK 29\06-53;4-AMNIO-3-CHLOROBENZIOC ACID;4-AMINO-3-CHLOROBENZOIC ACID;4-AMINO-3-CHLORBENZOIC ACID;3-CHLORO-4-AMINOBENZOIC ACID;4-Amino-3-chlorobenzioc acid;4-Amino-3-chlorobenz
• CAS NO: 2486-71-7
• Molecular Formula: C₇H₆ClNO₂
• Molecular Weight: 171.58
• EINECS: 219-630-4
• Product Categories: Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts;pharmacetical;Phenylacetic acid;Miscellaneous;Benzenes;Aromatic Amino AcidsCarbonyl Compounds;C7;Carboxylic Acids;Peptide Synthesis;Unnatural Amino Acid Derivatives;API Intermediate
• Mol File: 2486-71-7.mol
• Article Data: 10

Chemical Properties

• Melting Point: 228 °C
• Boiling Point: 341.2 °C at 760 mmHg
• Flash Point: 160.2 °C
• Appearance: off-white solid
• Density: 1.476 g/cm³
• Vapor Pressure: 3.15E-05mmHg at 25°C
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: soluble in Methanol
• PKA: 4.49±0.10(Predicted)
• CAS DataBase Reference: 4-Amino-3-chlorobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Amino-3-chlorobenzoic acid(2486-71-7)
• EPA Substance Registry System: 4-Amino-3-chlorobenzoic acid(2486-71-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26-36/37
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 2486-71-7(Hazardous Substances Data)

Usage

Description

4-Amino-3-chlorobenzoic acid is an organic compound characterized by its white powder form. It is a derivative of benzoic acid with an amino group at the 4th position and a chlorine atom at the 3rd position. 4-Amino-3-chlorobenzoic acid is known for its potential applications in various industries due to its unique chemical properties.

Uses

Used in Pharmaceutical Industry:
4-Amino-3-chlorobenzoic acid is used as a reagent for the synthesis of 1H-Pyrrolo[3,2-c]pyridine inhibitors. These inhibitors target mitotic kinase MPS1, which is overexpressed in cancer cell lines. By inhibiting MPS1, these compounds can potentially disrupt the cell division process in cancer cells, leading to their death and providing a therapeutic approach to cancer treatment.
The chemical properties of 4-Amino-3-chlorobenzoic acid, such as its reactivity and structural features, make it a valuable component in the development of new drugs and pharmaceutical compounds. Its application in the synthesis of MPS1 inhibitors highlights its potential in contributing to the fight against cancer.

InChI:InChI=1/C7H6ClNO2/c8-5-3-4(7(10)11)1-2-6(5)9/h1-3H,9H2,(H,10,11)/p-1

Upstream product

• 74114-62-8 4-acetamido-3-chlorobenzoic acid 
• 556-08-1 p-(acetylamino)benzoic acid 
• 21803-75-8 4-amino-3-chlorobenzonitrile 
• 18931-78-7 N-(2-chloro-4-methylphenyl)acetamide 
• 84228-44-4 methyl 4-amino-3-chlorobenzoate 
• 82765-44-4 1-amino-2-chloro-4-carboethoxybenzene 
• 150-13-0 4-amino-benzoic acid 

Downstream Products

• 126645-57-6 4-Amino-N-(4-benzyl-morpholin-2-ylmethyl)-3-chloro-benzamide 
• 70500-02-6 2-(3-chloro-4-aminophenyl)-6⁽⁵⁾-aminobenzimidazole 
• 194809-34-2 N-(4-amino-3-chlorobenzoyl)-(αS,γR)-γ-fluoroglutamic acid α,γ-diisopropyl ester 
• 84228-44-4 methyl 4-amino-3-chlorobenzoate 
• 1000068-64-3 3-chloro-4-[(6-chloropyrazin-2-yl)amino]benzoic acid 
• 113372-69-3 (4-amino-3-chlorophenyl)methanol 
• 253863-27-3 [(S)-5-[(S)-2-((R)-2-Allyloxycarbonylamino-propionylamino)-3-phenyl-propionylamino]-5-(2-chloro-4-hydroxymethyl-phenylcarbamoyl)-pentyl]-carbamic acid allyl ester 
• 253863-31-9 Carbonic acid 4-{(S)-6-allyloxycarbonylamino-2-[(S)-2-((R)-2-allyloxycarbonylamino-propionylamino)-3-phenyl-propionylamino]-hexanoylamino}-3-chloro-benzyl ester 4-nitro-phenyl ester 
• 253863-32-0 C₆₁H₆₉ClN₆O₂₀ 
• 194809-36-4 (2S,4R)-2-{3-Chloro-4-[(2,4-diamino-pteridin-6-ylmethyl)-amino]-benzoylamino}-4-fluoro-pentanedioic acid diisopropyl ester 
• 851202-78-3 4-amino-3-chloro-N-thiazol-2-yl-benzamide 
• 755039-51-1 C₂₀H₂₂ClN₅O₃ 
• 851091-96-8 1-[2-(4-amino-3-chloro-benzoylamino)-3,3-dimethyl-butyryl]-pyrrolidine-2-carboxylic acid (2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide 

Relevant articles and documents

Highly selective oxidative monochlorination to synthesize organic intermediates: 2-Chlorotoluene, 2-chloroaniline, 2-chlorophenol, and 2-chloro-4-methylphenol

An alternative manufacturing process scheme was developed to synthesize monochloro-substituted aromatic compounds in high selectivity, involving oxidalive chlorination by using HCI-H2O2. Thus, 2-chlorotoluene, 2-chloroaniline, and 2-chlorophenol were synthesized by oxidative chlorination followed by desulphonation or decarboxylation. Oxidative chlorination of 4-methylbenzenesulphonic acid, 4-methylbenzoic acid, 4-aminobenzoic acid, and 4-hydroxybenzoic acid by using a suitable ratio of reactantr:HCI:H2O2, and their subsequent desulphonation or decarboxylation, gave 60-85% yield of the desired products. Oxidative chlorination of 4-methylphenol by using HCI-H2O2 gave as high as 98% selectivity to the desired 2-chloro-4-methylphenol.

N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES

The invention relates to N-thiazol-2-yl-benzamide derivatives of the formula I in the description wherein the variables are as defined in the claims. The compounds are A2A-receptor ligands, such as antagonists, agonists, reverse agonists or partial agonists, and are useful in the treatment of neurological and psychiatric disorders where an A2A-receptor is implicated.

Drug evolution concept in drug design: 1. Hybridization method

A novel concept, "drug evolution", is proposed to develop chemical libraries that have a high probability of finding drugs or drug candidates. It converts biological evolution into chemical evolution. In this paper, we present "hybridization" drug evolution, which is the equivalent of sexual recombination of parental genomes in biological evolution. The hybridization essentially shuffles the building blocks of the parent drugs and ought to drug(s); no drug evolution can otherwise occur. We hybridized two drugs, benzocaine and metoclopramide and generated 16 molecules that include the parent drugs, four known drugs, and two molecules whose therapeutic activities are reported. The unusually high number of drugs and drug candidates in the library encourages high expectations of finding new drug(s) or drug candidate(s) within the remaining eight compounds. Interestingly, the therapeutic applications of the eight drugs or drug candidates in the library are fairly diverse as 38 therapeutic applications and 25 molecular targets are counted. Therefore, the library fits as a general chemical library for unspecified therapeutic activities. The hybridization of other two drugs, aspirin and cresotamide, is also described to demonstrate the generality of the method.